Simplex Trading, LLC Savara Inc Transaction History

Simplex Trading, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$3.66 - $5.34 $92,737 - $135,304	25,338 Added 252.9%	35,357 $142,000
Q1 2024 Apr 25, 2024	BUY	$4.19 - $5.59 $29,426 - $39,258	7,023 Added 234.41%	10,019 $49,000
Q4 2023 Feb 02, 2024	BUY	$3.18 - $4.9 $9,527 - $14,680	2,996 New	2,996 $14,000
Q1 2020 Apr 29, 2020	SELL	$1.91 - $4.08 $20,253 - $43,264	-10,604 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$0.71 - $4.91 $7,298 - $50,474	-10,280 Reduced 49.22%	10,604 $47,000
Q3 2019 Oct 15, 2019	BUY	$2.16 - $3.2 $45,109 - $66,828	20,884 New	20,884 $55,000
Q2 2019 Jul 26, 2019	SELL	$2.37 - $11.7 $104,066 - $513,746	-43,910 Closed	0 $0
Q1 2019 Apr 18, 2019	BUY	$6.71 - $8.6 $261,106 - $334,651	38,913 Added 778.73%	43,910 $0
Q4 2018 Jan 16, 2019	BUY	$6.27 - $10.92 $22,314 - $38,864	3,559 Added 247.5%	4,997 $37,000
Q3 2018 Oct 23, 2018	SELL	$10.49 - $12.87 $60,747 - $74,530	-5,791 Reduced 80.11%	1,438 $16,000
Q2 2018 Jul 30, 2018	BUY	$8.55 - $13.76 $58,319 - $93,856	6,821 Added 1671.81%	7,229 $81,000
Q1 2018 Apr 26, 2018	BUY	$8.99 - $14.95 $3,667 - $6,099	408 New	408 $3,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.